Replies to post #116767 on Biotech Values

[genisi]

CEPH has been busy lately

They should, generic threats are near and its IP position is weak plus Nuvigil switch isn't great, pain drugs and Treanda's sales seem to flattened.

Caution on the piece from the Pluristem board - it is from biomedreports.com.